Clinical Trials · NCT02023463
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Active Not Recruiting
- Sponsor
- Thomas Jefferson University
- Enrollment
- 25
- Start date
- Apr 2014
- Locations
- 1 site, United States
- Primary endpoint
- Acute toxicities, monitored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 criteria